Value snapshots of 3 frontline treatment options for ovarian cancer were constructed using the ASCO value framework in a recent study. Investigators looked at trials that evaluated 1) dose-dense paclitaxel, 2) intraperitoneal (IP)/intravenous (IV) chemotherapy, or 3) concurrent plus maintenance bevacizumab. They used the ASCO value framework to calculate net health benefit (NHB) relative to drug-acquisition cost. Among the results:

• NHB of dose-dense paclitaxel received 38 NHB points (out of a maximum of 180) at an additional cost of $16/cycle.
• IP cisplatin/IV + IP paclitaxel received 29 points at an additional cost of $1,629/cycle.
• Concurrent plus maintenance bevacizumab as used in the Gynecologic Oncology Group study received 24 points at an additional cost of $7,581/cycle.
• This same treatment as used in the Seventh International Collaborative Ovarian Neoplasm study received 6 points at an additional cost of $3,790/cycle.
• The NHB points-to-dollar ratios were 2.4, 0.018, and 0.003, respectively.